查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179614

細胞系和膜市場：按產品、供應商、類型、最終用戶分類：2021-2031 年全球機會分析和行業預測

Cell Line and Membrane Market By Products, By Source, By Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 346 Pages | 商品交期: 2-3個工作天內

價格

2021 年全球細胞系和膜市場價值 453304 萬美元，2031 年達到 1057456 萬美元，2022 年至 2031 年的複合年增長率為 8.8，預計將創下歷史新高。

細胞係是永久建立的細胞培養物，在適當的新鮮培養基和空間下可以無限生長，經常用於代替原代細胞來研究生物過程。 轉染、選擇和單細胞克隆都是細胞系生成過程的一部分。 不同類型的細胞用於製備不同的細胞系。 細胞係可以在受控環境中逐漸改變它們的細胞結構、生理學和基因組成。 細胞係來源於單細胞，用於生產融合蛋白、單克隆抗體、疫苗等。

細胞系使科學研究發生了革命性的變化，在疫苗生產、藥物代謝和細胞毒性檢測、抗體生產、基因功能研究、人造組織（人工皮膚）生成、生物化合物（治療性蛋白）合成等方面得到了廣泛應用。

市場增長的主要驅動力是癌症和慢性病的增加、人口老齡化以及疫苗生產數量的增加。 此外，藥物開發活動的增加、哺乳動物細胞在細胞系生產中的使用增加以及表達載體設計技術進步的激增也是推動市場增長的關鍵因素。 例如，根據國際癌症研究機構的數據，2020 年亞洲將診斷出 9,503,710 例新的癌症病例。

然而，嚴格的監管框架加上穩定電網的緩慢發展阻礙了市場增長。 相反，新興國家和低收入國家醫療保健市場的興起、流行病和流行病風險的增加預計將在預測期內為市場增長提供有利可圖的機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章細胞系和膜市場：按產品分類

  • 概覽
    • 市場規模和預測
  • 培養基和試劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 培養基/試劑細胞系/膜市場：按類型
      • 血清市場規模和預測：按地區
      • 文化媒體市場規模和預測：按地區
      • 試劑市場規模和預測：按地區
  • 設備
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 細胞系/膜裝置市場：按類型
      • 生物安全櫃市場規模和預測：按地區
      • 細胞計數器和活力系統的市場規模和預測：按地區
      • 孵化器市場規模和預測：按地區
      • 離心機市場規模和預測：按地區
      • 生物反應器市場規模趨勢和預測：按地區
      • 存儲設備的市場規模和預測：按地區
      • 其他市場規模和預測：按地區
  • 配件和消耗品
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章細胞系和膜市場：按供應商分類

  • 概覽
    • 市場規模和預測
  • 非哺乳動物細胞系
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 非哺乳動物細胞系細胞系和膜市場：按類型
      • 昆蟲市場規模和預測：按地區
      • 兩棲動物市場規模和預測：按地區
  • 哺乳動物細胞系
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章細胞系和膜市場：按類型分類

  • 概覽
    • 市場規模和預測
  • 重組細胞系
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 原代細胞系
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 雜交瘤
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 連續細胞系
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章細胞系和膜市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 生物技術、製藥業
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 學術和研究機構
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 8 章細胞系和膜市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按產品
      • 北美媒體、試劑細胞系和膜市場類型
      • 北美細胞系和膜市場：按類型分類
    • 北美市場規模和預測：按供應商分類
      • 北美非哺乳動物細胞系細胞系和膜市場：按類型分類
    • 北美市場規模和預測：按類型
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按產品
      • 歐洲培養基/試劑細胞系/膜市場：按類型分類
      • 歐洲細胞系和膜市場：按類型分類
    • 歐洲市場規模和預測：按供應商分類
      • 歐洲非哺乳動物細胞系細胞系和膜市場：按類型分類
    • 歐洲市場規模和預測：按類型
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按產品
      • 亞太地區細胞培養基和試劑市場：按類型分類
      • 亞太地區細胞系和膜市場：按類型分類
    • 亞太地區的市場規模和預測：按供應來源
      • 亞太地區非哺乳動物細胞系細胞系和膜市場：按類型分類
    • 亞太市場規模和預測：按類型
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按產品
      • LAMEA 培養基/試劑細胞系/膜市場：按類型分類
      • LAMEA 細胞培養裝置和膜市場：按類型分類
    • LAMEA 細胞系和膜市場規模和預測：按供應商分類
      • LAMEA 非哺乳動物細胞系細胞系和膜市場：按類型分類
    • LAMEA 市場規模和預測：按類型
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第九章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第十章公司簡介

  • Advanced Instruments LLC
  • AGC Biologics
  • Cytiva Lifesciences
  • Sartorius
  • Cellgenix Gmbh
  • Premas Biotech
  • Selexis SA
  • Samsung Biologics
  • Lonza
  • Thermofisher Scientific Inc
  • PromoCell
  • ProBioGen
Product Code: A13858

The global cell line and membrane market was valued at $4,533.04 million in 2021, and is projected to reach $10,574.56 million by 2031, registering a CAGR of 8.8% from 2022 to 2031.A cell line is a permanently established cell culture that will multiply indefinitely in a given appropriate fresh medium and space and is frequently used to investigate biological processes in place of primary cells. Transfection, selection, and single-cell cloning are all a part of the cell line generation process. Various types of cells are used to create different cell lines. Cell lines allow for the gradual changes in cell structure, physiology, and genetic makeup in a controlled setting. . Cell lines are derived from single cells and are used to make fusion proteins, monoclonal antibodies, and vaccines.

Cell lines have revolutionized scientific research and they are widely used in the production of vaccine, testing drug metabolism & cytotoxicity, antibody production, study of gene function, generation of artificial tissues (artificial skin), and synthesis of biological compounds (therapeutic proteins).

The key factors that drive the growth of market are rise in the prevalence of cancer & chronic diseases, rise in geriatric population, and increase in number of vaccine production. In addition, the rise in novel drug development activities, growth in use of mammalian cell for cell line production, and surge in technological advancements in expression vector design are the key factors that boost the market growth. For instance, according to the International Agency of Cancer Research, 9,503,710 new cancer cases were diagnosed in Asia in 2020.

However, the strict regulatory framework coupled with the time-consuming process for the development of stable lines hampers the market growth. Conversely, emerging healthcare market in developing countries & low-income countries and increase in the risk of pandemic & communicable diseases are expected to provide lucrative opportunity for the growth of market during the forecast period. 

The cell line and membrane market is segmented on the basis of product, source, type, end user, and region. By product, the market is fragmented into media & reagents, equipment, accessories, and consumables. By source, it is bifurcated into mammalian cell line and non-mammalian cell line. On the basis of type, the market is categorized into recombinant cell type, hybridomas, continuous cell line and primary cell line. By end user, the market is divided into biotech companies, academic and research institutes and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the cell line and membrane market share in 2021 and is anticipated to remain dominant during the forecast period owing to rise in the prevalence of cancer, increased use of media & reagents for cell line development, and presence of major key players in the region.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to rise in prevalence of chronic diseases and increase in geriatric population in developing countries.

The key players that operate in the cell line and membrane market are Advanced Instruments LLC, AGC Biologics, Cytiva Lifesciences, Sartorius Cellgenix Gmbh, Premas Biotech, Selexis SA, Lonza, Samsung Biologics, PromoCell, Thermofisher Scientific Inc, Imegenex India Pvt. Ltd., and ProBioGen

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cell line and membrane market analysis from 2021 to 2031 to identify the prevailing cell line and membrane market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cell line and membrane market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cell line and membrane market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Products

  • Media and Reagents
    • Type
    • Serum
    • Media
    • Reagents
  • Equipments
    • Type
    • Biosafety Cabinets
    • Cell Counters and Viability Systems
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage Equipment
    • Others
  • Accessories and Consumables

By Source

  • Non Mammalian Cell Line
    • Type
    • Insects
    • Amphibians
  • Mammalian Cell Line

By Type

  • Hybridomas
  • Continuous cell lines
  • Recombinant cell lines
  • Primary cell lines

By End User

  • Biotechnology and Pharmaceutical Industries
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Advanced Instruments LLC
    • AGC Biologics
    • Cytiva Lifesciences
    • Sartorius
    • Cellgenix Gmbh
    • Premas Biotech
    • Selexis SA
    • Samsung Biologics
    • Lonza
    • Thermofisher Scientific Inc
    • PromoCell
    • ProBioGen

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CELL LINE AND MEMBRANE MARKET, BY PRODUCTS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Media and Reagents
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Media and Reagents Cell Line and Membrane Market by Type
      • 4.2.4.1 Serum Market size and forecast, by region
      • 4.2.4.2 Media Market size and forecast, by region
      • 4.2.4.3 Reagents Market size and forecast, by region
  • 4.3 Equipments
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Equipments Cell Line and Membrane Market by Type
      • 4.3.4.1 Biosafety Cabinets Market size and forecast, by region
      • 4.3.4.2 Cell Counters and Viability Systems Market size and forecast, by region
      • 4.3.4.3 Incubators Market size and forecast, by region
      • 4.3.4.4 Centrifuges Market size and forecast, by region
      • 4.3.4.5 Bioreactors Market size and forecast, by region
      • 4.3.4.6 Storage Equipment Market size and forecast, by region
      • 4.3.4.7 Others Market size and forecast, by region
  • 4.4 Accessories and Consumables
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: CELL LINE AND MEMBRANE MARKET, BY SOURCE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Non Mammalian Cell Line
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Non Mammalian Cell Line Cell Line and Membrane Market by Type
      • 5.2.4.1 Insects Market size and forecast, by region
      • 5.2.4.2 Amphibians Market size and forecast, by region
  • 5.3 Mammalian Cell Line
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: CELL LINE AND MEMBRANE MARKET, BY TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Recombinant cell lines
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Primary cell lines
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Hybridomas
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Continuous cell lines
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country

CHAPTER 7: CELL LINE AND MEMBRANE MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Biotechnology and Pharmaceutical Industries
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Academic and Research Institutes
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country
  • 7.4 Others
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market analysis by country

CHAPTER 8: CELL LINE AND MEMBRANE MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Products
      • 8.2.2.1 North America Media and Reagents Cell Line and Membrane Market by Type
      • 8.2.2.2 North America Equipments Cell Line and Membrane Market by Type
    • 8.2.3 North America Market size and forecast, by Source
      • 8.2.3.1 North America Non Mammalian Cell Line Cell Line and Membrane Market by Type
    • 8.2.4 North America Market size and forecast, by Type
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Products
      • 8.2.6.1.2 Market size and forecast, by Source
      • 8.2.6.1.3 Market size and forecast, by Type
      • 8.2.6.1.4 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Products
      • 8.2.6.2.2 Market size and forecast, by Source
      • 8.2.6.2.3 Market size and forecast, by Type
      • 8.2.6.2.4 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Products
      • 8.2.6.3.2 Market size and forecast, by Source
      • 8.2.6.3.3 Market size and forecast, by Type
      • 8.2.6.3.4 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Products
      • 8.3.2.1 Europe Media and Reagents Cell Line and Membrane Market by Type
      • 8.3.2.2 Europe Equipments Cell Line and Membrane Market by Type
    • 8.3.3 Europe Market size and forecast, by Source
      • 8.3.3.1 Europe Non Mammalian Cell Line Cell Line and Membrane Market by Type
    • 8.3.4 Europe Market size and forecast, by Type
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Products
      • 8.3.6.1.2 Market size and forecast, by Source
      • 8.3.6.1.3 Market size and forecast, by Type
      • 8.3.6.1.4 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by Products
      • 8.3.6.2.2 Market size and forecast, by Source
      • 8.3.6.2.3 Market size and forecast, by Type
      • 8.3.6.2.4 Market size and forecast, by End User
      • 8.3.6.3 UK
      • 8.3.6.3.1 Market size and forecast, by Products
      • 8.3.6.3.2 Market size and forecast, by Source
      • 8.3.6.3.3 Market size and forecast, by Type
      • 8.3.6.3.4 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by Products
      • 8.3.6.4.2 Market size and forecast, by Source
      • 8.3.6.4.3 Market size and forecast, by Type
      • 8.3.6.4.4 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by Products
      • 8.3.6.5.2 Market size and forecast, by Source
      • 8.3.6.5.3 Market size and forecast, by Type
      • 8.3.6.5.4 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Products
      • 8.3.6.6.2 Market size and forecast, by Source
      • 8.3.6.6.3 Market size and forecast, by Type
      • 8.3.6.6.4 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Products
      • 8.4.2.1 Asia-Pacific Media and Reagents Cell Line and Membrane Market by Type
      • 8.4.2.2 Asia-Pacific Equipments Cell Line and Membrane Market by Type
    • 8.4.3 Asia-Pacific Market size and forecast, by Source
      • 8.4.3.1 Asia-Pacific Non Mammalian Cell Line Cell Line and Membrane Market by Type
    • 8.4.4 Asia-Pacific Market size and forecast, by Type
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Market size and forecast, by Products
      • 8.4.6.1.2 Market size and forecast, by Source
      • 8.4.6.1.3 Market size and forecast, by Type
      • 8.4.6.1.4 Market size and forecast, by End User
      • 8.4.6.2 China
      • 8.4.6.2.1 Market size and forecast, by Products
      • 8.4.6.2.2 Market size and forecast, by Source
      • 8.4.6.2.3 Market size and forecast, by Type
      • 8.4.6.2.4 Market size and forecast, by End User
      • 8.4.6.3 Australia
      • 8.4.6.3.1 Market size and forecast, by Products
      • 8.4.6.3.2 Market size and forecast, by Source
      • 8.4.6.3.3 Market size and forecast, by Type
      • 8.4.6.3.4 Market size and forecast, by End User
      • 8.4.6.4 India
      • 8.4.6.4.1 Market size and forecast, by Products
      • 8.4.6.4.2 Market size and forecast, by Source
      • 8.4.6.4.3 Market size and forecast, by Type
      • 8.4.6.4.4 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by Products
      • 8.4.6.5.2 Market size and forecast, by Source
      • 8.4.6.5.3 Market size and forecast, by Type
      • 8.4.6.5.4 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Market size and forecast, by Products
      • 8.4.6.6.2 Market size and forecast, by Source
      • 8.4.6.6.3 Market size and forecast, by Type
      • 8.4.6.6.4 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Products
      • 8.5.2.1 LAMEA Media and Reagents Cell Line and Membrane Market by Type
      • 8.5.2.2 LAMEA Equipments Cell Line and Membrane Market by Type
    • 8.5.3 LAMEA Market size and forecast, by Source
      • 8.5.3.1 LAMEA Non Mammalian Cell Line Cell Line and Membrane Market by Type
    • 8.5.4 LAMEA Market size and forecast, by Type
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Products
      • 8.5.6.1.2 Market size and forecast, by Source
      • 8.5.6.1.3 Market size and forecast, by Type
      • 8.5.6.1.4 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Products
      • 8.5.6.2.2 Market size and forecast, by Source
      • 8.5.6.2.3 Market size and forecast, by Type
      • 8.5.6.2.4 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by Products
      • 8.5.6.3.2 Market size and forecast, by Source
      • 8.5.6.3.3 Market size and forecast, by Type
      • 8.5.6.3.4 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by Products
      • 8.5.6.4.2 Market size and forecast, by Source
      • 8.5.6.4.3 Market size and forecast, by Type
      • 8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 Advanced Instruments LLC
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 AGC Biologics
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Cytiva Lifesciences
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Sartorius
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Cellgenix Gmbh
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Premas Biotech
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Selexis SA
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Samsung Biologics
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 Lonza
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 Thermofisher Scientific Inc
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments
  • 10.11 PromoCell
    • 10.11.1 Company overview
    • 10.11.2 Company snapshot
    • 10.11.3 Operating business segments
    • 10.11.4 Product portfolio
    • 10.11.5 Business performance
    • 10.11.6 Key strategic moves and developments
  • 10.12 ProBioGen
    • 10.12.1 Company overview
    • 10.12.2 Company snapshot
    • 10.12.3 Operating business segments
    • 10.12.4 Product portfolio
    • 10.12.5 Business performance
    • 10.12.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 2. CELL LINE AND MEMBRANE MARKET, FOR MEDIA AND REAGENTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. CELL LINE AND MEMBRANE MARKET FOR MEDIA AND REAGENTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL MEDIA AND REAGENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 5. CELL LINE AND MEMBRANE MARKET, FOR SERUM, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. CELL LINE AND MEMBRANE MARKET, FOR MEDIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. CELL LINE AND MEMBRANE MARKET, FOR REAGENTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. CELL LINE AND MEMBRANE MARKET, FOR EQUIPMENTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. CELL LINE AND MEMBRANE MARKET FOR EQUIPMENTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL EQUIPMENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 11. CELL LINE AND MEMBRANE MARKET, FOR BIOSAFETY CABINETS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. CELL LINE AND MEMBRANE MARKET, FOR CELL COUNTERS AND VIABILITY SYSTEMS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. CELL LINE AND MEMBRANE MARKET, FOR INCUBATORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. CELL LINE AND MEMBRANE MARKET, FOR CENTRIFUGES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. CELL LINE AND MEMBRANE MARKET, FOR BIOREACTORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. CELL LINE AND MEMBRANE MARKET, FOR STORAGE EQUIPMENT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. CELL LINE AND MEMBRANE MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. CELL LINE AND MEMBRANE MARKET, FOR ACCESSORIES AND CONSUMABLES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. CELL LINE AND MEMBRANE MARKET FOR ACCESSORIES AND CONSUMABLES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. GLOBAL CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 21. CELL LINE AND MEMBRANE MARKET, FOR NON MAMMALIAN CELL LINE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. CELL LINE AND MEMBRANE MARKET FOR NON MAMMALIAN CELL LINE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. GLOBAL NON MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 24. CELL LINE AND MEMBRANE MARKET, FOR INSECTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. CELL LINE AND MEMBRANE MARKET, FOR AMPHIBIANS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. CELL LINE AND MEMBRANE MARKET, FOR MAMMALIAN CELL LINE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. CELL LINE AND MEMBRANE MARKET FOR MAMMALIAN CELL LINE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. GLOBAL CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 29. CELL LINE AND MEMBRANE MARKET, FOR RECOMBINANT CELL LINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 30. CELL LINE AND MEMBRANE MARKET FOR RECOMBINANT CELL LINES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. CELL LINE AND MEMBRANE MARKET, FOR PRIMARY CELL LINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 32. CELL LINE AND MEMBRANE MARKET FOR PRIMARY CELL LINES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 33. CELL LINE AND MEMBRANE MARKET, FOR HYBRIDOMAS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 34. CELL LINE AND MEMBRANE MARKET FOR HYBRIDOMAS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 35. CELL LINE AND MEMBRANE MARKET, FOR CONTINUOUS CELL LINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 36. CELL LINE AND MEMBRANE MARKET FOR CONTINUOUS CELL LINES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 37. GLOBAL CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 38. CELL LINE AND MEMBRANE MARKET, FOR BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 39. CELL LINE AND MEMBRANE MARKET FOR BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 40. CELL LINE AND MEMBRANE MARKET, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 41. CELL LINE AND MEMBRANE MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 42. CELL LINE AND MEMBRANE MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 43. CELL LINE AND MEMBRANE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 44. CELL LINE AND MEMBRANE MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 45. NORTH AMERICA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 46. NORTH AMERICA MEDIA AND REAGENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 47. NORTH AMERICA EQUIPMENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. NORTH AMERICA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 49. NORTH AMERICA NON MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 50. NORTH AMERICA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. NORTH AMERICA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 52. NORTH AMERICA CELL LINE AND MEMBRANE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. U.S. CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 54. U.S. CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 55. U.S. CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 56. U.S. CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 57. CANADA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 58. CANADA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 59. CANADA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. CANADA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 61. MEXICO CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 62. MEXICO CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 63. MEXICO CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. MEXICO CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. EUROPE CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 66. EUROPE MEDIA AND REAGENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. EUROPE EQUIPMENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 68. EUROPE CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 69. EUROPE NON MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 70. EUROPE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. EUROPE CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 72. EUROPE CELL LINE AND MEMBRANE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 73. GERMANY CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 74. GERMANY CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 75. GERMANY CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 76. GERMANY CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 77. FRANCE CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 78. FRANCE CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 79. FRANCE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. FRANCE CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 81. UK CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 82. UK CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 83. UK CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 84. UK CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 85. ITALY CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 86. ITALY CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 87. ITALY CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 88. ITALY CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. SPAIN CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 90. SPAIN CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 91. SPAIN CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 92. SPAIN CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 93. REST OF EUROPE CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 94. REST OF EUROPE CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 95. REST OF EUROPE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 96. REST OF EUROPE CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 97. ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 98. ASIA-PACIFIC MEDIA AND REAGENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 99. ASIA-PACIFIC EQUIPMENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 101. ASIA-PACIFIC NON MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 102. ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 103. ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 104. ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 105. JAPAN CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 106. JAPAN CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 107. JAPAN CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 108. JAPAN CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 109. CHINA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 110. CHINA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 111. CHINA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 112. CHINA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 113. AUSTRALIA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 114. AUSTRALIA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 115. AUSTRALIA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 116. AUSTRALIA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 117. INDIA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 118. INDIA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 119. INDIA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 120. INDIA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 121. SOUTH KOREA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 122. SOUTH KOREA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 123. SOUTH KOREA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 124. SOUTH KOREA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 125. REST OF ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 126. REST OF ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 127. REST OF ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 128. REST OF ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 129. LAMEA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 130. LAMEA MEDIA AND REAGENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 131. LAMEA EQUIPMENTS CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 132. LAMEA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 133. LAMEA NON MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 134. LAMEA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 135. LAMEA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 136. LAMEA CELL LINE AND MEMBRANE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 137. BRAZIL CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 138. BRAZIL CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 139. BRAZIL CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 140. BRAZIL CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 141. SAUDI ARABIA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 142. SAUDI ARABIA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 143. SAUDI ARABIA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 144. SAUDI ARABIA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 145. SOUTH AFRICA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 146. SOUTH AFRICA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 147. SOUTH AFRICA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 148. SOUTH AFRICA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 149. REST OF LAMEA CELL LINE AND MEMBRANE MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 150. REST OF LAMEA CELL LINE AND MEMBRANE MARKET, BY SOURCE, 2021-2031 ($MILLION)
  • TABLE 151. REST OF LAMEA CELL LINE AND MEMBRANE MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 152. REST OF LAMEA CELL LINE AND MEMBRANE MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 153.ADVANCED INSTRUMENTS LLC: COMPANY SNAPSHOT
  • TABLE 154.ADVANCED INSTRUMENTS LLC: OPERATING SEGMENTS
  • TABLE 155.ADVANCED INSTRUMENTS LLC: PRODUCT PORTFOLIO
  • TABLE 156.ADVANCED INSTRUMENTS LLC: NET SALES,
  • TABLE 157.ADVANCED INSTRUMENTS LLC: KEY STRATERGIES
  • TABLE 158.AGC BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 159.AGC BIOLOGICS: OPERATING SEGMENTS
  • TABLE 160.AGC BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 161.AGC BIOLOGICS: NET SALES,
  • TABLE 162.AGC BIOLOGICS: KEY STRATERGIES
  • TABLE 163.CYTIVA LIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 164.CYTIVA LIFESCIENCES: OPERATING SEGMENTS
  • TABLE 165.CYTIVA LIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 166.CYTIVA LIFESCIENCES: NET SALES,
  • TABLE 167.CYTIVA LIFESCIENCES: KEY STRATERGIES
  • TABLE 168.SARTORIUS: COMPANY SNAPSHOT
  • TABLE 169.SARTORIUS: OPERATING SEGMENTS
  • TABLE 170.SARTORIUS: PRODUCT PORTFOLIO
  • TABLE 171.SARTORIUS: NET SALES,
  • TABLE 172.SARTORIUS: KEY STRATERGIES
  • TABLE 173.CELLGENIX GMBH: COMPANY SNAPSHOT
  • TABLE 174.CELLGENIX GMBH: OPERATING SEGMENTS
  • TABLE 175.CELLGENIX GMBH: PRODUCT PORTFOLIO
  • TABLE 176.CELLGENIX GMBH: NET SALES,
  • TABLE 177.CELLGENIX GMBH: KEY STRATERGIES
  • TABLE 178.PREMAS BIOTECH: COMPANY SNAPSHOT
  • TABLE 179.PREMAS BIOTECH: OPERATING SEGMENTS
  • TABLE 180.PREMAS BIOTECH: PRODUCT PORTFOLIO
  • TABLE 181.PREMAS BIOTECH: NET SALES,
  • TABLE 182.PREMAS BIOTECH: KEY STRATERGIES
  • TABLE 183.SELEXIS SA: COMPANY SNAPSHOT
  • TABLE 184.SELEXIS SA: OPERATING SEGMENTS
  • TABLE 185.SELEXIS SA: PRODUCT PORTFOLIO
  • TABLE 186.SELEXIS SA: NET SALES,
  • TABLE 187.SELEXIS SA: KEY STRATERGIES
  • TABLE 188.SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 189.SAMSUNG BIOLOGICS: OPERATING SEGMENTS
  • TABLE 190.SAMSUNG BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 191.SAMSUNG BIOLOGICS: NET SALES,
  • TABLE 192.SAMSUNG BIOLOGICS: KEY STRATERGIES
  • TABLE 193.LONZA: COMPANY SNAPSHOT
  • TABLE 194.LONZA: OPERATING SEGMENTS
  • TABLE 195.LONZA: PRODUCT PORTFOLIO
  • TABLE 196.LONZA: NET SALES,
  • TABLE 197.LONZA: KEY STRATERGIES
  • TABLE 198.THERMOFISHER SCIENTIFIC INC: COMPANY SNAPSHOT
  • TABLE 199.THERMOFISHER SCIENTIFIC INC: OPERATING SEGMENTS
  • TABLE 200.THERMOFISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
  • TABLE 201.THERMOFISHER SCIENTIFIC INC: NET SALES,
  • TABLE 202.THERMOFISHER SCIENTIFIC INC: KEY STRATERGIES
  • TABLE 203.PROMOCELL: COMPANY SNAPSHOT
  • TABLE 204.PROMOCELL: OPERATING SEGMENTS
  • TABLE 205.PROMOCELL: PRODUCT PORTFOLIO
  • TABLE 206.PROMOCELL: NET SALES,
  • TABLE 207.PROMOCELL: KEY STRATERGIES
  • TABLE 208.PROBIOGEN: COMPANY SNAPSHOT
  • TABLE 209.PROBIOGEN: OPERATING SEGMENTS
  • TABLE 210.PROBIOGEN: PRODUCT PORTFOLIO
  • TABLE 211.PROBIOGEN: NET SALES,
  • TABLE 212.PROBIOGEN: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CELL LINE AND MEMBRANE MARKET SEGMENTATION
  • FIGURE 2.CELL LINE AND MEMBRANE MARKET,2021-2031
  • FIGURE 3.CELL LINE AND MEMBRANE MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CELL LINE AND MEMBRANE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.CELL LINE AND MEMBRANE MARKET,BY PRODUCTS,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MEDIA AND REAGENTS CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF EQUIPMENTS CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ACCESSORIES AND CONSUMABLES CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 16.CELL LINE AND MEMBRANE MARKET,BY SOURCE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF NON MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MAMMALIAN CELL LINE CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 19.CELL LINE AND MEMBRANE MARKET,BY TYPE,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF RECOMBINANT CELL LINES CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PRIMARY CELL LINES CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HYBRIDOMAS CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS CELL LINES CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 24.CELL LINE AND MEMBRANE MARKET,BY END USER,2021(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF ACADEMIC AND RESEARCH INSTITUTES CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS CELL LINE AND MEMBRANE MARKET,2021-2031(%)
  • FIGURE 28.CELL LINE AND MEMBRANE MARKET BY REGION,2021
  • FIGURE 29.U.S. CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 30.CANADA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 31.MEXICO CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 32.GERMANY CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 33.FRANCE CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 34.UK CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 35.ITALY CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 36.SPAIN CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF EUROPE CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 38.JAPAN CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 39.CHINA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 40.AUSTRALIA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 41.INDIA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH KOREA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF ASIA-PACIFIC CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 44.BRAZIL CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 45.SAUDI ARABIA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 46.SOUTH AFRICA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 47.REST OF LAMEA CELL LINE AND MEMBRANE MARKET,2021-2031($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52.COMPETITIVE DASHBOARD
  • FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 54.ADVANCED INSTRUMENTS LLC.: NET SALES ,($MILLION)
  • FIGURE 55.AGC BIOLOGICS.: NET SALES ,($MILLION)
  • FIGURE 56.CYTIVA LIFESCIENCES.: NET SALES ,($MILLION)
  • FIGURE 57.SARTORIUS.: NET SALES ,($MILLION)
  • FIGURE 58.CELLGENIX GMBH.: NET SALES ,($MILLION)
  • FIGURE 59.PREMAS BIOTECH.: NET SALES ,($MILLION)
  • FIGURE 60.SELEXIS SA.: NET SALES ,($MILLION)
  • FIGURE 61.SAMSUNG BIOLOGICS.: NET SALES ,($MILLION)
  • FIGURE 62.LONZA.: NET SALES ,($MILLION)
  • FIGURE 63.THERMOFISHER SCIENTIFIC INC.: NET SALES ,($MILLION)
  • FIGURE 64.PROMOCELL.: NET SALES ,($MILLION)
  • FIGURE 65.PROBIOGEN.: NET SALES ,($MILLION)